Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new pandemic surged around them. By a year later, 66 million American adults had gotten at least one dose of a COVID-19 vaccine, at no cost to them.

Now, a new study shows how wise that national investment in testing, buying and delivering the first vaccines was.